Nkarta (Nasdaq:NKTX), a clinical-stage biopharma developing engineered NK cell therapies for autoimmune diseases, will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.
On June 30 at 2 p.m. ET, President Nadir Mahmood will join a webcast fireside chat on Nkarta’s investigational CAR-NK therapy for B cell-mediated autoimmune diseases, with a replay available for about 90 days.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – NKTX
+1.80%
1 alert
+1.80%Session close to close
$207.48MMarket Cap
0.0xRel. Volume
In the Jun 26 session, NKTX gained 1.80%, reflecting a mild positive market reaction.
This announcement highlights continued visibility for Nkarta’s CAR-NK autoimmune program via a June ...
Analysis
This announcement highlights continued visibility for Nkarta’s CAR-NK autoimmune program via a June 30 conference fireside chat. Investors may watch for incremental clinical detail, while the active S-3 shelf for up to $350,000,000 of securities remains a dilution overhang.
Key Figures
Conference time:2 p.m. ETConference date:June 30Webcast replay duration:90 days
"a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies"
Natural killer (NK) cell therapies use a type of immune cell that can find and destroy diseased cells — such as cancer — either after being grown and boosted outside the body or after being modified to work better. Investors care because these therapies represent a growing class of targeted treatments with the potential for high clinical benefit and commercial value, but they also carry scientific and regulatory risk similar to other advanced biotechnologies.
car-nk cell therapymedical
"updates on the company’s investigational CAR-NK cell therapy to treat B cell-mediated"
CAR-NK cell therapy uses a patient's or donor immune cells called natural killer (NK) cells that are genetically equipped with a targeting receptor (CAR) to find and destroy cancer cells. Think of it as giving trained guard dogs a custom scent to track intruders; the approach can be faster to deploy and potentially safer than some other cell therapies. Investors care because successful CAR-NK programs can drive clinical trial milestones, regulatory approvals, and scalable product models that affect company value and future revenue.
SOUTH SAN FRANCISCO, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in next week’s H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.
At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside chat to share updates on the company’s investigational CAR-NK cell therapy to treat B cell-mediated autoimmune diseases.
A simultaneous webcast of the discussion will be available on the investors section of Nkarta’s website, and a replay will be archived on the website for approximately 90 days.
About Nkarta Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for people living with autoimmune diseases. By harnessing the power of the innate immune system to eliminate pathogenic B cells driving the autoimmune response, Nkarta is advancing novel cell therapies engineered for deep therapeutic impact. The on-demand availability and outpatient dosing of our CAR-NK cells enables a broad population of patients with different autoimmune conditions to conveniently access NK cell therapy in community health settings. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact: Nadir Mahmood Nkarta, Inc. nmahmood@nkartatx.com
FAQ
What did Nkarta (NASDAQ:NKTX) announce about the H.C. Wainwright Cell Therapy Virtual Conference on June 30, 2026?
Nkarta announced it will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. According to Nkarta, President Nadir Mahmood will join a 2 p.m. ET fireside chat focused on its investigational CAR-NK cell therapy.
When is Nkarta’s (NKTX) fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference?
Nkarta’s fireside chat is scheduled for 2 p.m. ET on Tuesday, June 30. According to Nkarta, President Nadir Mahmood will provide updates on the company’s investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases during this virtual conference session.
What topic will Nkarta (NKTX) discuss at the H.C. Wainwright Cell Therapy Virtual Conference?
Nkarta will share updates on its investigational CAR-NK cell therapy to treat B cell-mediated autoimmune diseases. According to Nkarta, President Nadir Mahmood will discuss this program during a 2 p.m. ET fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.
How can investors watch Nkarta’s (NKTX) June 30, 2026 conference fireside chat?
Investors can watch Nkarta’s fireside chat via a simultaneous webcast available on the investors section of Nkarta’s website. According to Nkarta, the online stream will cover updates on its investigational CAR-NK therapy for B cell-mediated autoimmune diseases.
Will a replay of Nkarta’s (NASDAQ:NKTX) H.C. Wainwright conference webcast be available to investors?
Yes, a replay of Nkarta’s conference webcast will be archived on its website. According to Nkarta, the replay of President Nadir Mahmood’s June 30 fireside chat will remain accessible in the investors section for approximately 90 days after the event.
What type of therapies is Nkarta (NKTX) developing as highlighted in its H.C. Wainwright conference participation?
Nkarta is developing engineered natural killer (NK) cell therapies to treat autoimmune diseases. According to Nkarta, the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference fireside chat will focus on its investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases.
